Modulation of S1P in the Treatment of Autoimmune Diseases

Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results…